| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Nivolumab |
| Brand | Opdivo® |
| Indication | As monotherapy is indicated for the treatment of relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant and treatment with brentuximab vedotin. |
| Assessment Process | |
| Rapid review commissioned | 22/11/2016 |
| Rapid review completed | 18/01/2017 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended at the Submitted Price. |
The HSE has approved reimbursement following confidential price negotiations October 2017.